N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate–resistant patients with polycystic ovary syndrome

تاریخ : ۱۳۹۲/۱۲/۱۳ / تعداد بازدید : ۴۰۲

Abstract

Objective:

To evaluate the effect of N-acetyl-cysteine (NAC), a mucolytic drug with insulin sensitizing properties, as an adjuvant therapy in subjects with polycystic ovary syndrome (PCOS) resistant to clomiphene citrate (CC).

Design:

Placebo-controlled, double-blind randomized trial.

Setting:

University-based hospital and private infertility practice.

Patient(s):

One hundred fifty women diagnosed with CC-resistant PCOS, aged 18–39 years undergoing therapy for infertility were included.

Intervention(s):

The patients were assigned randomly to receive either NAC 1.2 g/d (group I) or placebo (group II) with CC 100 mg/d for 5 days starting at day 3 of the cycle.

Main Outcome Measure(s):

Ovulation rate and pregnancy rate (PR).

Result(s):

Combination of CC and NAC significantly increased both ovulation rate and PR in women with CC-resistant PCOS (49.3% vs. 1.3% and 21.3% vs. 0%, respectively). No cases of ovarian hyperstimulation syndrome (OHSS) were reported in the NAC group; two cases of miscarriage (12.5%) were reported.

Conclusion(s):

The NAC as an adjuvant to CC was more effective than placebo for CC-resistant patients with PCOS. It is safe and well tolerated. (Fertil Steril_ 2005;83:367–70. ©2005 by American Society for Reproductive Medicine.)

view full article here: acetyl-cysteine

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate–resistant patients with polycystic ovary syndrome

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis